Compare American Well Corp (AMWL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Recursion Pharmaceuticals Inc — how do they compare? American Well Corp trades at $13.01 (market cap $230.98M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 7.7× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMWL | RXRX | |
|---|---|---|
Market Cap | $230.98M | $1.78B |
Sector | Health | Health |
52-Week High | $13.58 | $6.79 |
52-Week Low | $3.78 | $2.84 |
Enterprise Value | $38.01M | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL (American Well Corporation) trades at $13.52, up 4.56% today, with a bullish technical signal from moving averages. The company shows improving financial trends with narrowing losses—net income margin improved from -97.57% in 2022 to -35.75% in 2026—and positive earnings beats in recent quarters. Recent news highlights include a Defense Health Agency partnership intent and leadership changes at Amazon's healthcare unit involving an Amwell co-founder. Operating cash flow losses have decreased significantly from -$192M in 2022 to -$26M projected for 2026.
Outlook: AMWL's path to operating breakeven by Q4 2026 and reduced cash burn present a turnaround opportunity, but persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 33% buy ratings. The stock's valuation at P/S of 1.02 appears reasonable if growth resumes, but execution on profitability targets is critical for sustained upside.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
